Quinones as preventive agents in Alzheimer’s diseases: focus on NLRP3 inflammasomes

0 / 5 (0 votos)
Quinones as preventive agents in Alzheimer’s diseases: focus on NLRP3 inflammasomes

Journal of Pharmacy and Pharmacology

Fecha de publicación: 15 July 2020

Autores: Da‐bao Chen, Hua‐wu Gao, Cheng Peng, Shao‐qiang Pei, An‐ran Dai, Xue‐ting Yu,Peng Zhou,Yan Wang,Biao Cai

DOI: https://doi.org/10.1111/jphp.13332

Background: Alzheimer’s disease (AD) is a hidden neurological degenerative disease, which main clinical manifestations are cognitive dysfunction, memory impairment and mental disorders. Neuroinflammation is considered as a basic response of the central nervous system. NLRP3 (Nucleotide‐binding domain leucine‐rich repeat (NLR) and pyrin domain containing receptor 3) inflammasome is closely related to the occurrence of neuroinflammation. Activation of the NLRP3 inflammasome results in the release of cytokines, pore formation and ultimately pyroptosis, which has demonstrated one of the critical roles in AD pathogenesis. Inhibition of the activity of NLRP3 is one of the focuses of the research. Therefore, NLRP3 represents an attractive pharmacological target, and discovery compounds with good NLRP3 inhibitory activity are particularly important.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.